Please use this identifier to cite or link to this item: https://doi.org/10.1593/neo.10916
Title: Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma
Authors: Kannan, N.
Kang, I.
Kong, X.
Tang, J.
Perry, J.K.
Mohankumar, K.M.
Miller, L.D.
Liu, E.T.
Mertani, H.C.
Zhu, T.
Grandison, P.M.
Liu, D.-X.
Lobie, P.E. 
Issue Date: Dec-2010
Citation: Kannan, N., Kang, I., Kong, X., Tang, J., Perry, J.K., Mohankumar, K.M., Miller, L.D., Liu, E.T., Mertani, H.C., Zhu, T., Grandison, P.M., Liu, D.-X., Lobie, P.E. (2010-12). Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma. Neoplasia 12 (12) : 1041-1053. ScholarBank@NUS Repository. https://doi.org/10.1593/neo.10916
Abstract: We report herein that trefoil factor 3 (TFF3) is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma. Forced expression of TFF3 in mammary carcinoma cells increased cell proliferation and survival, enhanced anchorage-independent growth, and promoted migration and invasion. Moreover, forced expression of TFF3 increased tumor size in xenograft models. Conversely, depletion of endogenous TFF3 with small interfering RNA (siRNA) decreased the oncogenicity and invasiveness of mammary carcinoma cells. Neutralization of secreted TFF3 by antibody promoted apoptosis, decreased cell growth in vitro, and arrested mammary carcinoma xenograft growth. TFF3 expression was significantly correlated to decreased survival of estrogen receptor (ER)-positive breast cancer patients treated with tamoxifen. Forced expression of TFF3 in mammary carcinoma cells increased ER transcriptional activity, promoted estrogen-independent growth, and produced resistance to tamoxifen and fulvestrant in vitro and to tamoxifen in xenograft models. siRNA-mediated depletion or antibody inhibition of TFF3 significantly enhanced the efficacy of antiestrogens. Increased TFF3 expression was observed in tamoxifen-resistant (TAMR) cells and antibody inhibition of TFF3 in TAMR cells improved tamoxifen sensitivity. Functional antagonism of TFF3 therefore warrants consideration as a novel therapeutic strategy for mammary carcinoma. © 2010 Neoplasia Press, Inc. All rights reserved.
Source Title: Neoplasia
URI: http://scholarbank.nus.edu.sg/handle/10635/116661
ISSN: 15228002
DOI: 10.1593/neo.10916
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

34
checked on Aug 11, 2018

WEB OF SCIENCETM
Citations

32
checked on Jul 17, 2018

Page view(s)

25
checked on Jul 19, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.